SCHEMBL2391614

SCHEMBL2391614

NC(=O)[C@@H](O)c1ccccc1-c1cc(Cl)cc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.43
KCNA5 P22460 1/20 0.43
PTPRC P08575 1/20 0.41
SLC9A1 P19634 2/20 0.39
RORB Q92753 2/20 0.39
FGFR1 P11362 1/20 0.38
SRC P12931 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
PDK2 Q15119 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
CTSA P10619 1/20 0.36
IKBKB O14920 1/20 0.36
BCAT2 O15382 1/20 0.36
RXRA P19793 2/20 0.36
RXRB P28702 2/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393198 1.00 APP (0.43) APPKCNA5PTPRCSLC9A1RORB
SCHEMBL2393200 1.00 APP (0.43) APPKCNA5PTPRCSLC9A1RORB
SCHEMBL2395590 0.90 APP (0.42) APPKCNA5PTPRCSLC9A1FGFR1
SCHEMBL9890803 0.88 CHRM1 (0.46) SLC9A1RORBCNR2IKBKBRORC
SCHEMBL2392699 0.81 BCAT2 (0.55) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL2395264 0.81 BCAT2 (0.55) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL2395269 0.81 BCAT2 (0.55) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL2393512 0.80 APP (0.47) APPCTSA
SCHEMBL2391794 0.80 APP (0.50) APPCNR1CTSARXRARXRB
SCHEMBL9890691 0.80 KCNA5 (0.46) APPKCNA5PTPRCRORBCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 APP 2725/4885KCNA5 41/4885PTPRC 3747/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 APP 2725/4885KCNA5 41/4885PTPRC 3747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.